Literature DB >> 31205326

Baloxavir Marboxil.

Danial E Baker1.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.

Entities:  

Keywords:  Drug Information; Formulary Management/P & T; Infectious Diseases

Year:  2019        PMID： 31205326      PMCID： PMC6535926          DOI： 10.1177/0018578719841044

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  5 in total

1.  In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit.

Authors:  Takeshi Noshi; Mitsutaka Kitano; Keiichi Taniguchi; Atsuko Yamamoto; Shinya Omoto; Keiko Baba; Takashi Hashimoto; Kayo Ishida; Yukihiro Kushima; Kazunari Hattori; Makoto Kawai; Ryu Yoshida; Masanori Kobayashi; Tomokazu Yoshinaga; Akihiko Sato; Masatoshi Okamatsu; Yoshihiro Sakoda; Hiroshi Kida; Takao Shishido; Akira Naito
Journal:  Antiviral Res       Date:  2018-10-11       Impact factor: 5.970

2.  Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.

Authors:  Frederick G Hayden; Norio Sugaya; Nobuo Hirotsu; Nelson Lee; Menno D de Jong; Aeron C Hurt; Tadashi Ishida; Hisakuni Sekino; Kota Yamada; Simon Portsmouth; Keiko Kawaguchi; Takao Shishido; Masatsugu Arai; Kenji Tsuchiya; Takeki Uehara; Akira Watanabe
Journal:  N Engl J Med       Date:  2018-09-06       Impact factor: 91.245

3.  Evaluation of Drug-Drug Interaction Potential between Baloxavir Marboxil and Oseltamivir in Healthy Subjects.

Authors:  Nao Kawaguchi; Hiroki Koshimichi; Toru Ishibashi; Toshihiro Wajima
Journal:  Clin Drug Investig       Date:  2018-11       Impact factor: 2.859

4.  Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil.

Authors:  Shinya Omoto; Valentina Speranzini; Takashi Hashimoto; Takeshi Noshi; Hiroto Yamaguchi; Makoto Kawai; Keiko Kawaguchi; Takeki Uehara; Takao Shishido; Akira Naito; Stephen Cusack
Journal:  Sci Rep       Date:  2018-06-25       Impact factor: 4.379

5.  Safety, Tolerability, and Pharmacokinetics of the Novel Anti-influenza Agent Baloxavir Marboxil in Healthy Adults: Phase I Study Findings.

Authors:  Hiroki Koshimichi; Toru Ishibashi; Nao Kawaguchi; Chisako Sato; Akira Kawasaki; Toshihiro Wajima
Journal:  Clin Drug Investig       Date:  2018-12       Impact factor: 2.859
  5 in total
  1 in total

Review 1.  Emerging therapeutics in the management of COVID-19.

Authors:  Asim Kichloo; Michael Albosta; Akshay Kumar; Michael Aljadah; Mohamed Mohamed; Zain El-Amir; Farah Wani; Shakeel Jamal; Jagmeet Singh; Akif Kichloo
Journal:  World J Virol       Date:  2021-01-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.